Research, development, production and support of filovirus for clinical trials
Ended Awarded Last action
- Contract number
- HHSN26100046
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $9,555,363
Award facts
- Opportunity
-
- N01CO5240180 Solicitation number
- Operations and Technical Support for the Frederick National Laboratory for Cancer Research (FLNCR), a Federally Funded Research and Development Center (FFRDC) Award Notice · Posted Apr 27, 2015
- Contract value 100% obligated
- $9,555,363.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 561210 Facilities Support Services
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $9,555,363 |
About this award
This is a federal contract awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The $9,555,363.00 contract is for research, development, production, and support of filovirus for clinical trials. The contract has a completion date of September 19, 2022 and was initially awarded on September 20, 2017. It is a cost-plus-fixed-fee delivery order contract without a set-aside designation. Leidos Biomedical Research has previously served as a prime contractor and subcontractor for NIH research efforts in areas like cancer, HIV/AIDS, influenza, COVID-19, and gene therapy. The company also holds a larger $6.6 billion indefinite delivery contract from the National Cancer Institute to serve as a Federally Funded Research and Development Center (FFRDC) and provide a range of biomedical research and facilities support services.
Quick answers
Who was awarded contract HHSN26100046?
HHSN26100046 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 20, 2017.
How much is contract HHSN26100046 worth?
The government has obligated $9,555,363 on HHSN26100046.
Is contract HHSN26100046 an order under another contract?
Yes. HHSN26100046 is a delivery order under HHSN261201500003I, an indefinite delivery contract.
Was contract HHSN26100046 competed?
The extent of competition for HHSN26100046 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award